Half Year 2026 Siegfried Holding AG Earnings Call Transcript
Key Points
- Net sales grew 4.8% in local currencies, in line with expectations.
- Core EBITDA margin improved to 22.4% from 21.6% year-over-year.
- Integration of newly acquired US and Australian sites is on track, with strong customer interest and three concrete offers already submitted.
- EVOLVE+ strategy is delivering results, including a 31% increase in RFPs for Drug Products and 69 more RFPs for Drug Substances year-to-date.
- Strategic technology upgrades are progressing as planned, with the first sterile products shipped to the US from El Masnou and the new Minden facility now on stream.
- Currency headwinds from weaker USD and EUR against CHF negatively impacted sales by 2-3% in H1 2026.
- Operating cash flow decreased to CHF93.7 million from CHF149.6 million, driven by timing of tax payments, currency effects, and increased working capital from the acquisition.
- Net debt to core EBITDA increased to 2.3x following the acquisition, with a focus on deleveraging ahead.
- Seasonality is more pronounced this year, with a larger share of revenue recognition events scheduled for H2, leading to a stronger second-half weighting.
- Core financial expenses increased due to expanded bond financing, and input costs, particularly personnel expenses, continued to rise.
Good morning, and a warm welcome to all of you. I'm excited to present to you our half-year results 2026 together with Tania. Tania joined us two months ago, and it was a busy start for her with the integration of the recent acquisition. With her strong experience as a CFO of a public listed company, she is already running on full speed, so I'm very pleased to have her on board.
Now let's turn to our half-year results. The Siegfried team is delivering. Let me give you a summary on the upcoming slide.
The performance of the first half of the year is exactly according to plan. Growth is in line with our expectation. Net sales grew by 4.8% in local currencies. Also core EBITDA margin, we increased from 21.6% up to 22.4%. Integration of newly acquired sites is on track. I will give you more details later on. EVOLVE+ strategy, exciting progress. So I really will share -- give you more insights later on as well.
With these results, we laid a solid foundation for
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
